Numbers

Claude View

The Numbers

Kolte-Patil trades at ₹346 on a trailing P/E of 73x — not because earnings are great, but because FY24 was a write-off year and the market is pricing the FY25 recovery plus an expectation that FY26 launches and collections normalise. The single metric that rerates (or derates) the stock is operating cash conversion: FY25 delivered ₹2.82B of OCF after FY24's -₹1.11B, but the first nine months of FY26 show revenue still lumpy and margins thin. Until quarterly revenue and margins stabilise, the multiple stays fragile.

1. Price & valuation snapshot

2. The FY24 air pocket and the FY25 rebound

Revenue hit an all-time high of ₹17.17B in FY25 — but net income of ₹1.09B is still below FY23's ₹1.13B and well below FY18's ₹1.54B. FY24 showed the underlying operating leverage: a 9% revenue decline compressed operating margin from 13% to 1% and drove a ₹670M net loss. Real-estate revenue recognition is project-timing driven; the FY24 dip is more about lumpy project completions than structural demand.

3. Quarterly trajectory — the market's real-time signal

Q3 FY26 is the first positive-earnings quarter of FY26 after two loss quarters. Revenue at ₹2.65B is roughly half of the Q4 FY25 peak, and operating margin of 3% confirms that the typical H2 skew (Q4 dominance) is intact — investors should not mis-read H1 losses as deterioration. Real-estate revenue recognition concentrates when projects cross completion thresholds.

4. Cash generation — where the stock really lives

The FY24 inversion — OCF of -₹1.11B funded by ₹3.19B of financing (mostly debt drawdown) — is the clearest footprint of the project-completion air pocket. FY25's ₹2.82B OCF rebuild is roughly in line with the FY20–FY22 average. Net debt rose during the stressed period and has not yet been paid down in FY25 (financing -₹1.60B vs +₹3.19B the year prior).

5. Balance sheet — leverage doubled in the bad year

Total debt doubled from ₹5.6B (FY23) to ₹11.2B (FY24) as the company funded operations through the dry spell. Equity compressed from the FY24 loss. The Q2 FY26 balance sheet shows the fresh capital raise flowing in — equity jumped to ₹12.23B (reserves ₹11.34B vs ₹7.54B at FY25 end) while debt eased to ₹10.52B. This is the single most important balance-sheet shift in a decade.

6. Return on capital — cyclical, not structural

ROCE oscillates with project-recognition timing between 2% and 16% — it is not a signal of structural quality in this business. The 10-year median is ~13%. The market's implicit assumption in paying 73x trailing earnings is that FY26 ROCE normalises to the 13–14% range, not the 2% trough.

7. Working capital — inventory is the whole business

Inventory (land banks + WIP projects) sits at ~1,000 days — this is the business. The meaningful improvement is that working-capital days turned negative in FY24 and widened to -77 days in FY25, meaning customer advances are now financing operations instead of shareholders. This shift, if durable, is what justifies a premium multiple versus the peers.

8. Shareholding — promoter bought, not sold

Two signals to note: promoter holding rose from 69.45% to 73.81% between FY25 and Q2 FY26 (a rare 4.4-point increase — almost certainly a preferential allotment or warrant conversion into promoter hands), and FII stake more than doubled from ~4% to 8.77%. Insider conviction plus foreign-institutional accumulation is a positive setup entering the FY26 project-completion cycle.

9. Peer comparison — smallest in the peer set, richest multiple

At ~₹31B, KOLTEPATIL is the smallest listed peer in the set. The 73x P/E is inflated by a normalised-earnings base — if FY25's ₹1.09B net income held, the forward P/E on current price is closer to ~28x, in line with Oberoi and Godrej. The valuation anomaly is visual, not fundamental — but only if FY26 delivers.

10. Peer positioning — margin vs multiple

KOLTEPATIL sits in the bottom-left — low margin, high multiple — with only Sobha paying up more per rupee of earnings. The market is clearly paying for a margin-recovery optionality that has not yet shown in the FY25 print (10% op margin vs Brigade 28% and Oberoi 59%).

11. The two charts that matter most

Bottom line

What the numbers confirm: FY25 was a genuine recovery — revenue all-time high, OCF back to ₹2.82B, working-capital days negative, promoter stake raised. The balance sheet got fresh equity in Q2 FY26 (reserves ₹11.3B vs ₹7.5B at FY25 end). Analyst median target of ₹478 suggests the street is pricing the cycle re-entry, not a structural story.

What the numbers contradict: the 73x trailing P/E is not really 73x on a normalised base — it is the math of a low-earnings denominator. Ex-FY24, 5-year average ROCE is ~12% and margins oscillate, so this is not a high-quality compounder at any price.

What to watch next quarter: Q4 FY26 revenue and operating margin — the seasonal concentration of project recognition means Q4 will either confirm the FY25 pattern (₹7B+ revenue, 15%+ op margin) or reveal that FY26 is another slippage year. Also watch debt: if the fresh equity does not translate into ₹2–3B of debt reduction by FY26 close, the leverage story remains a concern.